Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

6.70USD
8:26pm GMT
Change (% chg)

$-0.42 (-5.90%)
Prev Close
$7.12
Open
$7.10
Day's High
$7.20
Day's Low
$6.51
Volume
91,606
Avg. Vol
89,455
52-wk High
$12.50
52-wk Low
$6.35

Latest Key Developments (Source: Significant Developments)

Elbit Imaging Announces Gamida Cell Appointed New Chairman
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Elbit Imaging Ltd ::ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL HAS APPOINTED A NEW CHAIRMAN OF THE BOARD.ELBIT IMAGING LTD - ROBERT BLUM CURRENTLY ALSO SERVES AS PRESIDENT AND CEO OF CYTOKINETICS.  Full Article

Cytokinetics And Cure SMA Renew And Expand Partnership To Advance Education And Awareness Of SMA
Thursday, 17 May 2018 

May 17 (Reuters) - Cytokinetics Inc ::CYTOKINETICS AND CURE SMA RENEW AND EXPAND PARTNERSHIP TO ADVANCE EDUCATION AND AWARENESS OF SMA.CYTOKINETICS INC - URE SMA, CO ANNOUNCED EXPANDED PARTNERSHIP TO INCREASE EDUCATION, AWARENESS AND FUNDRAISING FOR SPINAL MUSCULAR ATROPHY.  Full Article

Cytokinetics Qtrly Net Loss Per Share $0.75
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Cytokinetics Inc ::CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.‍ENROLLMENT IN GALACTIC-HF ON TRACK UNDER COLLABORATION WITH AMGEN; FINALIZING PLANS FOR SECOND PHASE 3 CLINICAL TRIAL IN 2018​.‍COMPANY ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $17 TO $23 MILLION FOR 2018​.QTRLY NET LOSS PER SHARE $0.75.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $25.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Cytokinetics Announces Progress Against Vision 2020
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Cytokinetics Inc ::CYTOKINETICS ANNOUNCES PROGRESS AGAINST VISION 2020.CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​.CYTOKINETICS INC - RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018.CYTOKINETICS INC - ‍ENROLLMENT OF PATIENTS IN GALACTIC-HF IS ON TRACK IN 2018​.  Full Article

Cytokinetics Inc announces negative results from VITALITY-ALS
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​.  Full Article

Cytokinetics enters into second amendment to certain loan and security agreement
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cytokinetics Inc ::Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015 .Cytokinetics - ‍original loan agreement, as amended by amendment, provides for secured growth capital term loans of up to $50.0 million​.  Full Article

Cytokinetics reports Q3 loss of ‍$0.60/shr​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Cytokinetics Inc :Cytokinetics, Inc. reports third quarter 2017 financial results.Q3 revenue $6.2 million versus I/B/E/S view $6.5 million.Cytokinetics Inc - qtrly loss per share ‍$0.60​.Cytokinetics Inc- ‍anticipates cash research and development expenses will be in range of $103 million to $107 million for 2017​.  Full Article

Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - Cytokinetics Inc :Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure.Cytokinetics - ‍pharmacokinetics, pharmacodynamics, safety, tolerability data from trial were consistent with previously reported results from COSMIC-HF​.Cytokinetics Inc - ‍ coincident with patient dosing in galactic-hf, Amgen will make a $10 million milestone payment to Cytokinetics​.  Full Article

Cytokinetics Q2 loss per share $0.60
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Cytokinetics Inc :Cytokinetics Inc reports second quarter 2017 financial results.Q2 revenue $3.1 million versus $5.8 million.Q2 loss per share $0.60.Q2 revenue view $8.3 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Cytokinetics Inc ::Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics inc - ‍company is eligible to earn $10 million milestone payment from amgen upon first patient dosing in Japan in phase 3 outcomes trial​.Cytokinetics inc - ‍phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure has met its pharmacokinetic primary endpoint​.Cytokinetics inc - ‍phase 2 clinical trial demonstrated statistically significant improvements in systolic ejection time (set), a secondary endpoint​.Cytokinetics inc - ‍cytokinetics is eligible to earn a $10 million milestone payment from amgen upon first dosing of a patient in Japan in Galactic-Hf​.  Full Article